The combination therapy of atezolizumab, obinutuzumab, and venetoclax has shown to be active in patients with untreated diffuse large B-cell lymphoma (DLBCL) - Richter’s syndrome (also called Richter's transformation. Richter's syndrome occurs when chronic lymphocytic leukemia (CLL) / small lymphocytic lymphoma (SLL) transforms into an aggressive lymphoma.
Dr. Brian Koffman reviews the study results presented at the International Conference on Malignant Lymphomas (ICML) in 2023.
Read the full article on CLL Society's website at: [ Ссылка ]
__________________________________________________________________________________________
CLL Society Website: [ Ссылка ]
Facebook: [ Ссылка ]
Twitter: [ Ссылка ]
LinkedIn: [ Ссылка ]
